Nasdaq:EDIT
Editas Medicine, Inc.
A CRISPR-based gene editing company developing therapies for serious monogenic diseases with a strong cash position but significant ongoing R&D burn.
Key Metrics
Investment Thesis
Bull Case
Investors may consider EDIT for its cutting-edge CRISPR platform with multiple late-stage assets poised for potential blockbuster approvals that could transform the company into a revenue-generating biotech leader. The strong balance sheet and successful history of partnering with top-tier pharma companies suggest a high probability of future commercial milestones being hit as clinical data progresses.
Bear Case
The stock carries substantial risk given the company's deep operating loss and lack of product sales, relying entirely on external capital markets to fund its expensive R&D pipeline. A single negative clinical trial outcome could deplete cash reserves rapidly and invalidate the current valuation based on future potential rather than current performance.
About Editas Medicine, Inc.
Editas Medicine, Inc. is a pioneering genetic medicine company focused on developing CRISPR/Cas9-based therapeutic candidates to treat serious monogenic diseases across various markets including oncology, hematology, and ophthalmology. The company primarily generates revenue through collaborations with large pharmaceutical partners and grants for research and development of its proprietary gene-editing technologies. Key products are currently in preclinical or clinical development stages, targeting conditions such as sickle cell disease, transthyretin amyloidosis, and various cancers.
Analysis
Management Discussion
While the company reported a slight increase in revenue to $32.3M, it continues to operate at a substantial net loss of $-237.1M driven by heavy investments in research and development totaling $199.2M. Cash reserves remain healthy at $135.4M after recent financing activities, providing runway to advance its clinical pipeline through pivotal trials.
Industry Overview
The gene editing sector is experiencing rapid growth as CRISPR technology matures and regulatory pathways become clearer, offering vast opportunities for treating previously incurable genetic disorders. However, the industry remains highly competitive with significant barriers to entry regarding intellectual property and manufacturing capabilities for complex therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $19.7M | $78.1M | $32.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $19.7M | $78.1M | $32.3M |
| Operating Expenses | $245.7M | $247.3M | $283.5M |
| Operating Income | $-225.9M | $-169.2M | $-251.2M |
| R&D | $175.0M | $177.7M | $199.2M |
| G&A | $70.7M | $69.7M | $72.0M |
| Stock-Based Comp | $29.3M | $19.8M | $21.4M |
| Depreciation | $6.3M | $6.1M | $5.8M |
| Other OpEx | $0 | $0 | $12.2M |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-225.9M | $-169.2M | $-251.2M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-225.9M | $-169.2M | $-251.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-220.4M | $-153.2M | $-237.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-220.4M | $-153.2M | $-237.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $356.8M | $340.8M | $289.3M |
| Cash & Equivalents | $141.5M | $123.7M | $131.5M |
| Marketable Securities | $202.8M | $199.5M | $138.4M |
| Prepaid Expenses | $7.3M | $7.5M | $3.1M |
| Other Current Assets | $5.1M | $10.2M | $16.3M |
| Long-Term Assets | $157.6M | $158.3M | $52.3M |
| PP&E (Net) | $15.6M | $12.0M | $14.5M |
| Operating Leases | $43.6M | $33.7M | $32.6M |
| LT Securities | $93.1M | $104.0M | $0 |
| Other LT Assets | $5.3M | $8.6M | $5.2M |
| Total Assets | $514.3M | $499.2M | $341.6M |
| Current Liabilities | $60.1M | $63.2M | $77.2M |
| Accounts Payable | $9.5M | $8.3M | $5.5M |
| Current Debt | — | — | $5.0M |
| Current Leases | $11.1M | $12.2M | $14.7M |
| Deferred Revenue | $8.2M | $8.2M | $6.2M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $93.5M | $86.8M | $130.1M |
| Long-Term Debt | — | — | $52.4M |
| LT Operating Leases | $32.9M | $24.4M | $20.4M |
| Other LT Liab | $0 | $1.8M | $3.1M |
| Total Liabilities | $153.6M | $150.1M | $207.3M |
| Shareholders' Equity | $360.7M | $349.1M | $134.3M |
| Retained Earnings | $-1.08B | $-1.23B | $-1.47B |
| AOCI | $-3.6M | $198.0K | $268.0K |
| Total L&E | $514.3M | $499.2M | $341.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-220.4M | $-153.2M | $-237.1M |
| Non-Cash Adjustments | $10.5M | $15.5M | $27.9M |
| Working Capital Changes | $32.6M | $5.6M | $-1.0M |
| Cash from Operations | $-177.3M | $-132.2M | $-210.3M |
| Capital Expenditures | $4.1M | $4.7M | $8.8M |
| Cash from Investing | $114.1M | $-3.7M | $162.1M |
| Cash from Financing | $1.3M | $118.0M | $56.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-62.0M | $-17.9M | $7.9M |
| Beginning Cash | $207.4M | $145.4M | $127.5M |
| Ending Cash | $145.4M | $127.5M | $135.4M |
Frequently Asked Questions
How does Editas Medicine, Inc. make money?
Revenue is driven by milestones and royalties from strategic collaborations with pharmaceutical partners (e.g., Pfizer, Regeneron) for specific therapeutic indications, as well as government grants and other research funding supporting the development of its gene-editing platform.
What are the main risks for EDIT?
Significant financial risk due to high cash burn rates exceeding $200M annually without current product revenue to offset losses; regulatory uncertainty surrounding gene editing approvals from the FDA and EMA could delay or limit market access for therapies; clinical trial failures for any of its numerous therapeutic candidates would result in substantial write-offs and potential loss of investor confidence.
What is EDIT's competitive advantage?
The company possesses a proprietary CRISPR/Cas9 technology platform that allows for precise genetic modifications; it has established a robust pipeline with multiple late-stage clinical trials nearing completion or recently initiated; and it maintains strategic partnerships with major biopharmaceutical giants providing capital and commercialization expertise.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.